Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease

Biochemical and Biophysical Research Communications
Ira L GoldknopfStanley H Appel

Abstract

We have used quantitative 2D gel electrophoresis to analyze serum proteins from 422 patients with neurodegenerative diseases and normal individuals in an unbiased approach to identify biomarkers. Differences in abnormal serum levels were found between amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and related disorders for 34 protein biomarker spots, nine of which were related to the complement system. Of these nine, four spots originated from the Complement C3b-alpha-chain (C3c(1), C3c(2a), C3c(2b), and C3dg). The C3c spots (C3c(1), C3c(2a), and C3c(2b)) had the same amino acid sequence and glycosylation, though only C3c(1) was phosphorylated. In addition, Complement Factors H, Bb, and Pre-Serum amyloid protein displayed different serum concentrations in ALS, PD, and normal sera, whereas Complement C4b gamma-chain and Complement Factor I did not. The differential expression of the complement proteins provides potentially useful biomarkers as well as evidence for the involvement of inflammatory processes in the pathogenesis of ALS and PD.

Associated Clinical Trials

References

Dec 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·L Anderson, N G Anderson
Dec 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·I L GoldknopfH Busch
May 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·M K Pangburn, H J Müller-Eberhard
Sep 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·J M WeilerD T Fearon
Dec 15, 1989·Neuroscience Letters·P L McGeerE G McGeer
Jul 1, 1985·Acta Neurologica Scandinavica·P Annunziata, N Volpi
May 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·L R OrrickH Busch
Nov 10, 1995·The Journal of Biological Chemistry·P García de FrutosB Dahlbäck
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·G A TennentM B Pepys
Mar 20, 1998·Annals of Neurology·C E ShawP N Leigh
Aug 4, 2001·Immunologic Research·H Rus, F Niculescu
Dec 19, 2002·Molecular & Cellular Proteomics : MCP·N Leigh Anderson, Norman G Anderson
Mar 14, 2003·Nature·Ruedi Aebersold, Matthias Mann
Nov 1, 2003·Science·Ted M Dawson, Valina L Dawson
Jan 30, 2004·Molecular & Cellular Proteomics : MCP·Sam Hanash
Mar 17, 2004·Current Opinion in Pharmacology·Weidong Le, Stanley H Appel
Apr 28, 2004·Parkinsonism & Related Disorders·Patrick L McGeer, Edith G McGeer
Jul 6, 2004·Clinical Biochemistry·C Nicole WhiteZhen Zhang
Oct 13, 2004·Prostate Cancer and Prostatic Diseases·H KurumaT Maeda
Nov 13, 2004·Cell Research·Varun RachakondaWei Dong LE
May 27, 2005·Neurobiology of Aging·Olga PletnikovaJuan C Troncoso
Oct 13, 2005·Brain : a Journal of Neurology·Carolyn F OrrGlenda M Halliday
Nov 9, 2005·American Journal of Alzheimer's Disease and Other Dementias·Sara M LippaHiroshi Mori
Nov 30, 2005·Journal of Neurochemistry·Srikanth RanganathanRobert Bowser
Dec 13, 2005·Molecular and Cellular Neurosciences·Jenny S HenkelStanley H Appel

❮ Previous
Next ❯

Citations

Oct 7, 2006·Molecular Diagnosis & Therapy·Christi Kolarcik, Robert Bowser
Aug 5, 2008·Journal of Neurology·E F GoodallK E Morrison
Jun 5, 2008·Journal of Neural Transmission·Ilse S PienaarJürgen Götz
May 5, 2012·Journal of Neural Transmission·Joanna TarasiukPiotr Lewczuk
Oct 29, 2013·Journal of Neuroimmunology·Maria C O RodriguesSvitlana Garbuzova-Davis
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ilan HalperinSilvia A Mandel
Oct 13, 2011·Nature Reviews. Neurology·Robert BowserJeremy Shefner
Apr 30, 2008·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Jeffrey C Smith, Daniel Figeys
Jul 24, 2008·PloS One·Rebecca BanerjeeHoward E Gendelman
May 5, 2012·PloS One·Richard S FinkelUNKNOWN Pilot Study of Biomarkers for Spinal Muscular Atrophy Trial Group
Sep 14, 2007·CNS Drugs·Edith G McGeer, Patrick L McGeer
Sep 30, 2014·Journal of Neuroimmunology·S MantovaniT M Woodruff
Oct 3, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Amaal AlDakheelAnthony E Lang
Oct 31, 2013·Proceedings of the National Academy of Sciences of the United States of America·Christian S LobsigerDon W Cleveland
Apr 28, 2007·Proceedings of the National Academy of Sciences of the United States of America·Christian S LobsigerDon W Cleveland
Sep 22, 2015·Expert Review of Clinical Immunology·Bryan Paul Morgan
Jan 5, 2013·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Christiaan G J SarisLeonard H van den Berg
Sep 3, 2009·Biochemical and Biophysical Research Communications·Ira L GoldknopfKaterina Markopoulou
Jun 10, 2011·Acta Neurologica Scandinavica·M RentzosI Evdokimidis
Mar 23, 2011·Journal of Neurochemistry·Jeban GanesalingamRobert Bowser
Apr 26, 2016·Oxidative Medicine and Cellular Longevity·Dolores Limongi, Sara Baldelli
Mar 13, 2010·Journal of Biomedicine & Biotechnology·Rhiannon L C H HuzarewichStephanie A Booth
Oct 27, 2014·International Immunology·Andrea MalaspinaSandra Amor
Nov 27, 2014·Frontiers in Cellular Neuroscience·Franca OrsiniMaria-Grazia De Simoni
Aug 8, 2009·Progress in Brain Research·V Ramaglia, F Baas
May 26, 2015·Journal of Neuroscience Methods·Mahlon A CollinsRobert Bowser
Jul 11, 2007·Expert Review of Molecular Diagnostics·Ira L Goldknopf
Mar 21, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Ashima SinhaRakesh Shukla
Oct 4, 2006·Neuron·Séverine BoilléeDon W Cleveland
May 15, 2007·Current Opinion in Neurology·Andis KlegerisPatrick L McGeer
May 16, 2007·Electrophoresis·Haleem J Issaq, Timothy D Veenstra
Nov 13, 2009·Annals of the New York Academy of Sciences·Gráinne C O'KeeffeRoger A Barker
Nov 23, 2018·Acta Neuropathologica·Madelyn E McCauley, Robert H Baloh
Feb 4, 2010·Expert Review of Proteomics·Garima SrivastavaMahendra Pratap Singh
Jul 9, 2008·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Angelina S PalmaJlia Costa
Jul 24, 2015·Journal of Cellular Physiology·Stewart Siyan CaoLynn Shi
Feb 13, 2020·International Journal of Molecular Sciences·Fabiana NovellinoGiuseppe Donato
Dec 4, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Trent M WoodruffPeter G Noakes
May 3, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Steffen HalbgebauerMarkus Otto
Apr 20, 2019·Frontiers in Neurology·Nick S VerberPamela J Shaw

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.